FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105449080> ?p ?o ?g. }

• W2105449080 endingPage "2" @default.
• W2105449080 startingPage "1" @default.
• W2105449080 abstract "Perspective on the paper by Kitchin et al ( see page 11) Pertussis vaccination is part of the backbone of global immunisation policy because of the high rates of disease in unimmunised populations and a mortality in early infancy of about 1 in 500. Most of the world’s children are immunised with whole-cell pertussis vaccines, which were used in the UK from the 1950s and have been highly effective in reducing pertussis-related morbidity and mortality. Whole-cell pertussis vaccines contain >3000 pertussis proteins as a suspension of killed organisms, can cause severe local reactions, and are associated with inconsolable crying and hospitalisations related to febrile seizures or hypotonic hyporesponsive episodes (HHE) after immunisation in infants. By contrast, acellular pertussis vaccines, containing ⩽5 purified proteins (components) from Bordetella pertussis , are far less reactogenic than whole-cell pertussis vaccines. The decision to replace whole-cell pertussis vaccine in the UK schedule with Pediacel (DTaP–IPV–Hib; Sanofi Pasteur, Lyon, France) in 2004 was good news for infants, as it has an improved reactogenicity profile when compared with whole-cell pertussis vaccines,1 and can be expected to lead to a marked reduction in these unpleasant severe adverse events. A similar acellular pertussis vaccine, Pentacel (DTaP–IPV–Hib), also manufactured by Sanofi Pasteur, was shown to reduce HHE-related hospitalisations by 67% and febrile seizures by 79% after introduction in Canada in the late 1990s.2The efficacy of new pertussis-containing vaccines is difficult to evaluate in immunised populations, and protection cannot be adequately assessed using immunogenicity measures alone, as serological correlates of protection are not clear.3 In addition to Pediacel, which contains five purified pertussis proteins, there are several other acellular pertussis vaccines available, with varying numbers of components and doses of proteins in them. Extrapolation from previous studies using similar vaccines is necessary in considering whether Pediacel might …" @default.
• W2105449080 created "2016-06-24" @default.
• W2105449080 creator A5065914659 @default.
• W2105449080 date "2007-01-01" @default.
• W2105449080 modified "2023-09-27" @default.
• W2105449080 title "New combination vaccines still need a boost" @default.
• W2105449080 cites W2015988281 @default.
• W2105449080 cites W2026386002 @default.
• W2105449080 cites W2065455554 @default.
• W2105449080 cites W2071047927 @default.
• W2105449080 cites W2074823372 @default.
• W2105449080 cites W2099827565 @default.
• W2105449080 cites W2113695132 @default.
• W2105449080 cites W2119917603 @default.
• W2105449080 cites W2135751078 @default.
• W2105449080 cites W2140698201 @default.
• W2105449080 cites W2144137490 @default.
• W2105449080 cites W2152287976 @default.
• W2105449080 cites W2152956317 @default.
• W2105449080 cites W2160879811 @default.
• W2105449080 cites W2328100509 @default.
• W2105449080 cites W2606926319 @default.
• W2105449080 cites W2466870107 @default.
• W2105449080 doi "https://doi.org/10.1136/adc.2006.106724" @default.
• W2105449080 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2083155" @default.
• W2105449080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17185438" @default.
• W2105449080 hasPublicationYear "2007" @default.
• W2105449080 type Work @default.
• W2105449080 sameAs 2105449080 @default.
• W2105449080 citedByCount "5" @default.
• W2105449080 countsByYear W21054490802012 @default.
• W2105449080 countsByYear W21054490802019 @default.
• W2105449080 crossrefType "journal-article" @default.
• W2105449080 hasAuthorship W2105449080A5065914659 @default.
• W2105449080 hasBestOaLocation W21054490802 @default.
• W2105449080 hasConcept C159047783 @default.
• W2105449080 hasConcept C177713679 @default.
• W2105449080 hasConcept C71924100 @default.
• W2105449080 hasConceptScore W2105449080C159047783 @default.
• W2105449080 hasConceptScore W2105449080C177713679 @default.
• W2105449080 hasConceptScore W2105449080C71924100 @default.
• W2105449080 hasIssue "1" @default.
• W2105449080 hasLocation W21054490801 @default.
• W2105449080 hasLocation W21054490802 @default.
• W2105449080 hasLocation W21054490803 @default.
• W2105449080 hasLocation W21054490804 @default.
• W2105449080 hasOpenAccess W2105449080 @default.
• W2105449080 hasPrimaryLocation W21054490801 @default.
• W2105449080 hasRelatedWork W1506200166 @default.
• W2105449080 hasRelatedWork W1995515455 @default.
• W2105449080 hasRelatedWork W2039318446 @default.
• W2105449080 hasRelatedWork W2048182022 @default.
• W2105449080 hasRelatedWork W2080531066 @default.
• W2105449080 hasRelatedWork W2748952813 @default.
• W2105449080 hasRelatedWork W2899084033 @default.
• W2105449080 hasRelatedWork W3032375762 @default.
• W2105449080 hasRelatedWork W3108674512 @default.
• W2105449080 hasRelatedWork W4252371801 @default.
• W2105449080 hasVolume "92" @default.
• W2105449080 isParatext "false" @default.
• W2105449080 isRetracted "false" @default.
• W2105449080 magId "2105449080" @default.
• W2105449080 workType "article" @default.